TIMP2 and TIMP3 have divergent roles in early renal tubulointerstitial injury

Kidney International

Volumn 85, Issue 1, 2014, Pages 82-93

  Wang, Zuocheng ^a   Famulski, Konrad ^a   Lee, Jiwon ^a   Das, Subhash K ^a   Wang, Xiuhua ^a   Halloran, Philip ^a   Oudit, Gavin Y ^a   Kassiri, Zamaneh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

fibrosis; gene expression; microarray; renal tubulointerstitial injury; TIMP2; TIMP3

Indexed keywords

CASPASE 3; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; GELATINASE A; SMAD2 PROTEIN; SMAD3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEFICIENCY; GENE EXPRESSION; GENETIC TRANSCRIPTION; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TUBULE DISORDER; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RENAL PROTECTION; RENAL TUBULOINTERSTITIAL INJURY; SIGNAL TRANSDUCTION; URETER OBSTRUCTION;

ACUTE KIDNEY INJURY; ADAM PROTEINS; ANIMALS; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED C57BL; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TUMOR NECROSIS FACTOR-ALPHA; URETERAL OBSTRUCTION;

EID: 84891559744     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.225     Document Type: Article

References (48)

1. Moore L, Fan D, Basu R et al. Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Fail Rev 2011; 17: 693-706.
2. Nuttall RK, Sampieri CL, Pennington CJ et al. Expression analysis of the entire MMP and TIMP gene families during mouse tissue development. FEBS Lett 2004; 563: 129-134. (Pubitemid 38471586)
3. Williamson RA, Marston FA, Angal S et al. Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP). Biochem J 1990; 268: 267-274. (Pubitemid 20193961)
4. Gomez DE, Alonso DF, Yoshiji H et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111-122. (Pubitemid 27455388)
5. Hernandez-Barrantes S, Toth M, Bernardo MM et al. Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J Biol Chem 2000; 275: 12080-12089. (Pubitemid 30237783)
6. Strongin AY, Collier I, Bannikov G et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995; 270: 5331-5338.
7. Kassiri Z, Oudit GY, Kandalam V et al. Loss of TIMP3 enhances interstitial nephritis and fibrosis. J Am Soc Nephrol 2009; 20: 1223-1235.
8. Schrimpf C, Xin C, Campanholle G et al. Pericyte TIMP3 and ADAMTS1 modulate vascular stability after kidney injury. J Am Soc Nephrol 2012; 23: 868-883.
9. English JL, Kassiri Z, Koskivirta I et al. Individual Timp deficiencies differentially impact pro-MMP-2 activation. J Biol Chem 2006; 281: 10337-10346. (Pubitemid 43864572)
10. Catania JM, Chen G, Parrish AR. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 2007; 292: F905-F911. (Pubitemid 46393417)
11. Kassiri Z, Defamie V, Hariri M et al. Simultaneous transforming growth factor beta-tumor necrosis factor activation and cross-talk cause aberrant remodeling response and myocardial fibrosis in Timp3-deficient heart. J Biol Chem 2009; 284: 29893-29904.
12. Kuncio GS, Neilson EG, Haverty T. Mechanisms of tubulointerstitial fibrosis. Kidney Int 1991; 39: 550-556.
13. Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis 2005; 12: 353-365. (Pubitemid 41376493)
14. Zhang G, Kernan KA, Collins SJ et al. Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals. J Am Soc Nephrol 2007; 18: 846-859. (Pubitemid 46434501)
15. Kim H, Oda T, Lopez-Guisa J et al. TIMP-1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2001; 12: 736-748. (Pubitemid 32246702)
16. Sato M, Muragaki Y, Saika S et al. Targeted disruption of TGF-beta1/ Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003; 112: 1486-1494. (Pubitemid 38056275)
17. Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 2009; 75: 1145-1152.
18. Nadin L, Butler AM, Farrell GC et al. Pretranslational down-regulation of cytochromes P450 2C11 and 3A2 in male rat liver by tumor necrosis factor alpha. Gastroenterology 1995; 109: 198-205.
19. Monshouwer M, McLellan RA, Delaporte E et al. Differential effect of pentoxifylline on lipopolysaccharide-induced downregulation of cytochrome P450. Biochem Pharmacol 1996; 52: 1195-1200. (Pubitemid 26356234)
20. Sewer MB, Morgan ET. Nitric oxide-independent suppression of P450 2C11 expression by interleukin-1beta and endotoxin in primary rat hepatocytes. Biochem Pharmacol 1997; 54: 729-737. (Pubitemid 27404633)
21. Famulski KS, Einecke G, Reeve J et al. Changes in the transcriptome in allograft rejection: IFN-gamma-induced transcripts in mouse kidney allografts. Am J Transplant 2006; 6: 1342-1354. (Pubitemid 44030317)
22. Einecke G, Melk A, Ramassar V et al. Expression of CTL associated transcripts precedes the development of tubulitis in T-cell mediated kidney graft rejection. Am J Transplant 2005; 5: 1827-1836. (Pubitemid 41039855)
23. Famulski KS, Broderick G, Einecke G et al. Transcriptome analysis reveals heterogeneity in the injury response of kidney transplants. Am J Transplant 2007; 7: 2483-2495. (Pubitemid 47561622)
24. Einecke G, Broderick G, Sis B et al. Early loss of renal transcripts in kidney allografts: relationship to the development of histologic lesions and alloimmune effector mechanisms. Am J Transplant 2007; 7: 1121-1130. (Pubitemid 46643125)
25. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448-1456. (Pubitemid 28516069)
26. Zheng Y, Saftig P, Hartmann D et al. Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNFalpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNFalpha convertase (TACE/ADAM17). J Biol Chem 2004; 279: 42898-42906. (Pubitemid 39372180)
27. Ferrara L, Gandhi M, Litton C et al. Chorionic villus sampling and the risk of adverse outcome in patients undergoing multifetal pregnancy reduction. American journal of obstetrics and gynecology 2008; 199: e401-e404.
28. Butler GS, Butler MJ, Atkinson SJ et al. The TIMP2 membrane type 1 metalloproteinase 'receptor' regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem 1998; 273: 871-880. (Pubitemid 28049179)
29. Ahmad K, Gandhi MS, Smith WC et al. Bilateral pleural effusions in congestive heart failure. The American journal of the medical sciences 2008; 335: 484-488.
30. Cheng S, Lovett DH, Gelatinase A. (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am J Pathol 2003; 162: 1937-1949. (Pubitemid 36613051)
31. Atkinson SJ, Crabbe T, Cowell S et al. Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes. J Biol Chem 1995; 270: 30479-30485. (Pubitemid 26005105)
32. Fan JM, Ng YY, Hill PA et al. Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int 1999; 56: 1455-1467. (Pubitemid 29451252)
33. Szczech LA, Golub ET, Springer G et al. Highly active antiretroviral therapy reduces urinary albumin excretion in women with HIV infection. J Acquir Immune Defic Syndr 2008; 48: 360-361.
34. Eddy AA, Kim H, Lopez-Guisa J et al. Interstitial fibrosis in mice with overload proteinuria: deficiency of TIMP-1 is not protective. Kidney Int 2000; 58: 618-628. (Pubitemid 30620011)
35. Chang HY, Sneddon JB, Alizadeh AA et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004; 2: E7.
36. Riss J, Khanna C, Koo S et al. Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma. Cancer Res 2006; 66: 7216-7224. (Pubitemid 44197701)
37. Hauser P, Kainz A, Perco P et al. Transcriptional response in the unaffected kidney after contralateral hydronephrosis or nephrectomy. Kidney Int 2005; 68: 2497-2507. (Pubitemid 43250996)
38. Meldrum KK, Misseri R, Metcalfe P et al. TNF-alpha neutralization ameliorates obstruction-induced renal fibrosis and dysfunction. Am J Physiol Regul Integr Comp Physiol 2007; 292: R1456-R1464. (Pubitemid 46557805)
39. Guo G, Morrissey J, McCracken R et al. Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. Am J Physiol 1999; 277: F766-F772.
40. Misseri R, Meldrum DR, Dinarello CA et al. TNF-alpha mediates obstruction-induced renal tubular cell apoptosis and proapoptotic signaling. Am J Physiol Renal Physiol 2005; 288: F406-F411. (Pubitemid 40105400)
41. Amour A, Slocombe PM, Webster A et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 1998; 435: 39-44. (Pubitemid 28432011)
42. Wang Z, Juttermann R, Soloway PD. TIMP-2 is required for efficient activation of proMMP-2 in vivo. J Biol Chem 2000; 275: 26411-26415.
43. Kandalam V, Basu R, Abraham T et al. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation. Circ Res 2010; 106: 796-808.
44. Kandalam V, Basu R, Moore L et al. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress. Circulation 2011; 124: 2094-2105.
45. Karsdal MA, Larsen L, Engsig MT et al. Matrix metalloproteinasedependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J Biol Chem 2002; 277: 44061-44067. (Pubitemid 36157833)
46. Einecke G, Reeve J, Sis B et al. A molecular classifier for predicting future graft loss in late kidney transplant biopsies. J Clin Invest 2010; 120: 1862-1872.
47. Kassiri Z, Oudit GY, Sanchez O et al. Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice. Circ Res 2005; 97: 380-390. (Pubitemid 41216143)
48. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.